Research progress on the mechanism of common inflammatory pathways in the pathogenesis and development of lymphoma

References

• Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumors of hemato-poietic and lymphoid tissues. 4th edition. Lyon (France): IARC Press. 2008.
   Google Scholar
• Thandra KC, Barsouk A, Saginala K, et al. Epidemiology of non-Hodgkin’s lymphoma. Med Sci. 2021;9(1):1. doi:10.3390/medsci9010005.
   Google Scholar
• Chu Y, Liu Y, Fang X, et al. The epidemiological patterns of non-Hodgkin lymphoma: global estimates of disease burden, risk factors, and temporal trends. Front Oncol. 2023;13:1059914. doi:10.3389/fonc.2023.1059914.
   PubMed Web of Science ®Google Scholar
• Health Commission of the People’s Republic of China N. National guidelines for diagnosis and treatment of malignant lymphoma 2022 in China (English version). Chin J Cancer Res. 2022;34(5):425–13.
   PubMed Web of Science ®Google Scholar
• Liu W, Liu J, Song Y, et al. Mortality of lymphoma and myeloma in China, 2004–2017: an observational study. J Hematol Oncol. 2019;12(1):22. doi:10.1186/s13045-019-0706-9.
   PubMed Web of Science ®Google Scholar
• Matasar MJ, Zelenetz AD. Overview of lymphoma diagnosis and management. Radiol Clin North Am. 2008;46(2):175–198, vii. doi:10.1016/j.rcl.2008.03.005.
   PubMed Web of Science ®Google Scholar
• Jiang M, Bennani NN, Feldman AL. Lymphoma classification update: T-cell lymphomas, Hodgkin lymphomas, and histiocytic/dendritic cell neoplasms. Expert Rev Hematol. 2017;10(3):239–249. doi:10.1080/17474086.2017.1281122.
   PubMed Web of Science ®Google Scholar
• Aldinucci D, Gloghini A, Pinto A, et al. The classical Hodgkin’s lymphoma microenvironment and its role in promoting tumor growth and immune escape. J Pathol. 2010;221(3):248–263. doi:10.1002/path.2711.
   PubMed Web of Science ®Google Scholar
• Bilotta MT, Antignani A, Fitzgerald DJ. Managing the TME to improve the efficacy of cancer therapy. Front Immunol. 2022;13(13):954992. doi:10.3389/fimmu.2022.954992.
   PubMedGoogle Scholar
• Liu WR, Shipp MA. Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program. 2017;2017(1):310–316. doi:10.1182/asheducation-2017.1.310.
   PubMedGoogle Scholar
• Jaeger A, Gambheer SMM, Sun X, et al. Activated granulocytes and inflammatory cytokine signaling drive T-cell lymphoma progression and disease symptoms. Blood. 2023;141(23):2824–2840. doi:10.1182/blood.2022015653.
   PubMed Web of Science ®Google Scholar
• Patil K, Kuttikrishnan S, Khan AQ, et al. Molecular pathogenesis of cutaneous T cell lymphoma: role of chemokines, cytokines, and dysregulated signaling pathways. Semin Cancer Biol. 2022;86(Pt 3):382–399. doi:10.1016/j.semcancer.2021.12.003.
   PubMedGoogle Scholar
• Aittomäki S, Pesu M. Therapeutic targeting of the jak/STAT pathway. Basic Clin Pharmacol Toxicol. 2014;114(1):18–23. doi:10.1111/bcpt.12164.
   PubMed Web of Science ®Google Scholar
• Hu X, Li J, Fu M, et al. The JAK/STAT signaling pathway: from bench to clinic. Signal Transduct Target Ther. 2021;6(1):402.
   PubMed Web of Science ®Google Scholar
• Fu XY. A transcription factor with SH2 and SH3 domains is directly activated by an interferon alpha-induced cytoplasmic protein tyrosine kinase(s). Cell. 1992;70(2):323–335. doi:10.1016/0092-8674(92)90106-m.
   PubMed Web of Science ®Google Scholar
• Zhong Z, Wen Z, Darnell JE.Jr. Stat3 and Stat4: members of the family of signal transducers and activators of transcription. Proc Natl Acad Sci U S A. 1994;91(11):4806–4810. doi:10.1073/pnas.91.11.4806.
   PubMed Web of Science ®Google Scholar
• Hou J, Schindler U, Henzel WJ, et al. An interleukin-4-induced transcription factor: IL-4 stat. Science. 1994;265(5179):1701–1706. doi:10.1126/science.8085155.
   PubMed Web of Science ®Google Scholar
• Horvath CM. STAT proteins and transcriptional responses to extracellular signals. Trends Biochem Sci. 2000;25(10):496–502. doi:10.1016/s0968-0004(00)01624-8.
   PubMed Web of Science ®Google Scholar
• Begitt A, Meyer T, van Rossum M, et al. Nucleocytoplasmic translocation of Stat1 is regulated by a leucine-rich export signal in the coiled-coil domain. Proc Natl Acad Sci U S A. 2000;97(19):10418–10423. doi:10.1073/pnas.190318397.
   PubMed Web of Science ®Google Scholar
• Kisseleva T, Bhattacharya S, Braunstein J, et al. Signaling through the JAK/STAT pathway, recent advances and future challenges. Gene. 2002;285(1–2):1–24. doi:10.1016/s0378-1119(02)00398-0.
   PubMed Web of Science ®Google Scholar
• Chen X, Vinkemeier U, Zhao Y, et al. Crystal structure of a tyrosine phosphorylated STAT-1 dimer bound to DNA. Cell. 1998;93(5):827–839. doi:10.1016/s0092-8674(00)81443-9.
   PubMed Web of Science ®Google Scholar
• Shuai K, Horvath CM, Huang LH, et al. Interferon activation of the transcription factor Stat91 involves dimerization through SH2-phosphotyrosyl peptide interactions. Cell. 1994;76(5):821–828. doi:10.1016/0092-8674(94)90357-3.
   PubMed Web of Science ®Google Scholar
• Bousoik E, Montazeri Aliabadi H. Do we know Jack’ about JAK? A closer look at JAK/STAT signaling pathway. Front Oncol. 2018;8:287. doi:10.3389/fonc.2018.00287.
   PubMed Web of Science ®Google Scholar
• Owen KL, Brockwell NK, Parker BS. JAK-STAT signaling: a double-edged sword of immune regulation and cancer progression. Cancers . 2019;11(12):2002. doi:10.3390/cancers11122002.
   PubMed Web of Science ®Google Scholar
• Zhao H, Wu L, Yan G, et al. Inflammation and tumor progression: signaling pathways and targeted intervention. Signal Transduct Target Ther. 2021;6(1):263.
   PubMed Web of Science ®Google Scholar
• Xin P, Xu X, Deng C, et al. The role of JAK/STAT signaling pathway and its inhibitors in diseases. Int Immunopharmacol. 2020;80:106210. doi:10.1016/j.intimp.2020.106210.
   PubMed Web of Science ®Google Scholar
• O’Shea JJ, Plenge R. JAK and STAT signaling molecules in immunoregulation and immune-mediated disease. Immunity. 2012;36(4):542–550. doi:10.1016/j.immuni.2012.03.014.
   PubMed Web of Science ®Google Scholar
• Ritz O, Guiter C, Castellano F, et al. Recurrent mutations of the STAT6 DNA binding domain in primary mediastinal B-cell lymphoma. Blood. 2009;114(6):1236–1242. doi:10.1182/blood-2009-03-209759.
   PubMed Web of Science ®Google Scholar
• Green MR, Monti S, Rodig SJ, et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood. 2010;116(17):3268–3277. doi:10.1182/blood-2010-05-282780.
   PubMed Web of Science ®Google Scholar
• Gaulard P, Harris NL, Pileri SA, et al. Primary mediastinal (thymic) large B-cell lymphoma. WHO classification of tumors of haematopoietic and lymphoid tissues. Geneva (Switzerland): WHO Press.2008:175–176.
   Google Scholar
• Stein H, von Wasielewski R, Poppema S, et al. Nodular sclerosis classical Hodgkin lymphoma. WHO classification of tumors of haematopoietic and lymphoid tissues. Geneva (Switzerland): WHO Press; 2008:249–250.
   Google Scholar
• Savage KJ, Monti S, Kutok JL, et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical hodgkin lymphoma. Blood. 2003;102(12):3871–3879. doi:10.1182/blood-2003-06-1841.
   PubMed Web of Science ®Google Scholar
• Phillips D, Matusiak M, Gutierrez BR, et al. Immune cell topography predicts response to PD-1 blockade in cutaneous T cell lymphoma. Nat Commun. 2021;12(1):6726. doi:10.1038/s41467-021-26974-6.
   PubMed Web of Science ®Google Scholar
• Wilcox RA. Cutaneous T-cell lymphoma: 2017 update on diagnosis, risk-stratification, and management. Am J Hematol. 2017;92(10):1085–1102. doi:10.1002/ajh.24876.
   PubMed Web of Science ®Google Scholar
• Mehta-Shah N, Horwitz SM, Ansell S, et al. NCCN guidelines insights: primary cutaneous lymphomas, version 2.2020. J Natl Compr Canc Netw. 2020;18(5):522–536. doi:10.6004/jnccn.2020.0022.
   PubMed Web of Science ®Google Scholar
• Tensen CP, Quint KD, Vermeer MH. Genetic and epigenetic insights into cutaneous T-cell lymphoma. Blood. 2022;139(1):15–33. doi:10.1182/blood.2019004256.
   PubMed Web of Science ®Google Scholar
• Gluud M, Pallesen EMH, Buus TB, et al. Malignant T cells induce skin barrier defects through cytokine-mediated JAK/STAT signaling in cutaneous T-cell lymphoma. Blood. 2023;141(2):180–193. doi:10.1182/blood.2022016690.
   PubMed Web of Science ®Google Scholar
• Nestle FO, Di Meglio P, Qin JZ, et al. Skin immune sentinels in health and disease. Nat Rev Immunol. 2009;9(10):679–691. doi:10.1038/nri2622.
   PubMed Web of Science ®Google Scholar
• Pendaries V, Malaisse J, Pellerin L, et al. Knockdown of filaggrin in a three-dimensional reconstructed human epidermis impairs keratinocyte differentiation. J Invest Dermatol. 2014;134(12):2938–2946. doi:10.1038/jid.2014.259.
   PubMed Web of Science ®Google Scholar
• Kezic S, Kemperman PM, Koster ES, et al. Loss-of-function mutations in the filaggrin gene lead to reduced level of natural moisturizing factor in the stratum corneum. J Invest Dermatol. 2008;128(8):2117–2119. doi:10.1038/jid.2008.29.
   PubMed Web of Science ®Google Scholar
• Koo GC, Tan SY, Tang T, et al. Janus kinase 3-activating mutations identified in natural killer/T-cell lymphoma. Cancer Discov. 2012;2(7):591–597. doi:10.1158/2159-8290.CD-12-0028.
   PubMed Web of Science ®Google Scholar
• Manshouri T, Quintás-Cardama A, Nussenzveig RH, et al. The JAK kinase inhibitor CP-690,550 suppresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation. Cancer Sci. 2008;99(6):1265–1273. doi:10.1111/j.1349-7006.2008.00817.x.
   PubMed Web of Science ®Google Scholar
• Rivera-Munoz P, Laurent AP, Siret A, et al. Partial trisomy 21 contributes to T-cell malignancies induced by JAK3-activating mutations in murine models. Blood Adv. 2018;2(13):1616–1627. doi:10.1182/bloodadvances.2018016089.
   PubMed Web of Science ®Google Scholar
• Cornejo MG, Kharas MG, Werneck MB, et al. Constitutive JAK3 activation induces lymphoproliferative syndromes in murine bone marrow transplantation models. Blood. 2009;113(12):2746–2754. doi:10.1182/blood-2008-06-164368.
   PubMed Web of Science ®Google Scholar
• Gozgit JM, Bebernitz G, Patil P, et al. Effects of the JAK2 inhibitor, AZ960, on pim/BAD/BCL-xL survival signaling in the human JAK2 V617F cell line SET-2. J Biol Chem. 2008;283(47):32334–32343. doi:10.1074/jbc.M803813200.
   PubMed Web of Science ®Google Scholar
• Tiacci E, Ladewig E, Schiavoni G, et al. Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma. Blood. 2018;131(22):2454–2465. doi:10.1182/blood-2017-11-814913.
   PubMed Web of Science ®Google Scholar
• Mathas S, Hartmann S, Küppers R. Hodgkin lymphoma: pathology and biology. Semin Hematol. 2016;53(3):139–147. doi:10.1053/j.seminhematol.2016.05.007.
   PubMed Web of Science ®Google Scholar
• Morin RD, Assouline S, Alcaide M, et al. Genetic landscapes of relapsed and refractory diffuse large B-cell lymphomas. Clin Cancer Res. 2016;22(9):2290–2300. doi:10.1158/1078-0432.CCR-15-2123.
   PubMed Web of Science ®Google Scholar
• Yildiz M, Li H, Bernard D, et al. Activating STAT6 mutations in follicular lymphoma. Blood. 2015;125(4):668–679. doi:10.1182/blood-2014-06-582650.
   PubMed Web of Science ®Google Scholar
• Dubois S, Viailly PJ, Mareschal S, et al. Next-Generation sequencing in diffuse large B-cell lymphoma highlights molecular divergence and therapeutic opportunities: a LYSA study. Clin Cancer Res. 2016;22(12):2919–2928. doi:10.1158/1078-0432.CCR-15-2305.
   PubMed Web of Science ®Google Scholar
• Scheeren FA, Diehl SA, Smit LA, et al. IL-21 is expressed in hodgkin lymphoma and activates STAT5: evidence that activated STAT5 is required for hodgkin lymphomagenesis. Blood. 2008;111(9):4706–4715. doi:10.1182/blood-2007-08-105643.
   PubMed Web of Science ®Google Scholar
• Zhang L, Yang J, Qian J, et al. Role of the microenvironment in mantle cell lymphoma: IL-6 is an important survival factor for the tumor cells. Blood. 2012;120(18):3783–3792. doi:10.1182/blood-2012-04-424630.
   PubMed Web of Science ®Google Scholar
• Kuruvilla J, MacDonald DA, Kouroukis CT, et al. Salvage chemotherapy and autologous stem cell transplantation for transformed indolent lymphoma: a subset analysis of NCIC CTG LY12. Blood. 2015;126(6):733–738. doi:10.1182/blood-2015-01-622084.
   PubMed Web of Science ®Google Scholar
• Ramis-Zaldivar JE, Gonzalez-Farre B, Nicolae A, et al. MAPK and JAK-STAT pathways dysregulation in plasmablastic lymphoma. Haematologica. 2021;106(10):2682–2693. doi:10.3324/haematol.2020.271957.
   PubMed Web of Science ®Google Scholar
• Shanbhag S, Ambinder RF. Hodgkin lymphoma: a review and update on recent progress. CA Cancer J Clin. 2018;68(2):116–132. doi:10.3322/caac.21438.
   PubMed Web of Science ®Google Scholar
• Diaz T, Navarro A, Ferrer G, et al. Lestaurtinib inhibition of the Jak/STAT signaling pathway in hodgkin lymphoma inhibits proliferation and induces apoptosis. PLOS One. 2011;6(4):e18856. doi:10.1371/journal.pone.0018856.
   PubMed Web of Science ®Google Scholar
• Bilanges B, Posor Y, Vanhaesebroeck B. PI3K isoforms in cell signalling and vesicle trafficking. Nat Rev Mol Cell Biol. 2019;20(9):515–534. doi:10.1038/s41580-019-0129-z.
   PubMed Web of Science ®Google Scholar
• Jafari M, Ghadami E, Dadkhah T, et al. PI3k/AKT signaling pathway: erythropoiesis and beyond. J Cell Physiol. 2019;234(3):2373–2385. doi:10.1002/jcp.27262.
   PubMed Web of Science ®Google Scholar
• Xu Z, Han X, Ou D, et al. Targeting PI3K/AKT/mTOR-mediated autophagy for tumor therapy. Appl Microbiol Biotechnol. 2020;104(2):575–587. doi:10.1007/s00253-019-10257-8.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Qian Y, Sun Z, et al. Role of PI3K in the progression and regression of atherosclerosis. Front Pharmacol. 2021;12:632378. doi:10.3389/fphar.2021.632378.
   PubMed Web of Science ®Google Scholar
• Glaviano A, Foo ASC, Lam HY, et al. PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer. Mol Cancer. 2023;22(1):138. doi:10.1186/s12943-023-01827-6.
   PubMed Web of Science ®Google Scholar
• Nepstad I, Hatfield KJ, Grønningsæter IS, et al. The PI3K-Akt-mTOR signaling pathway in human acute myeloid leukemia (AML) cells. Int J Mol Sci. 2020;21(8):2907. doi:10.3390/ijms21082907.
   PubMed Web of Science ®Google Scholar
• Tewari D, Patni P, Bishayee A, et al. Natural products targeting the PI3K-Akt-mTOR signaling pathway in cancer: a novel therapeutic strategy. Semin Cancer Biol. 2022;80:1–17. doi:10.1016/j.semcancer.2019.12.008.
   PubMed Web of Science ®Google Scholar
• Cornejo MG, Mabialah V, Sykes SM, et al. Crosstalk between NOTCH and AKT signaling during murine megakaryocyte lineage specification. Blood. 2011;118(5):1264–1273. doi:10.1182/blood-2011-01-328567.
   PubMed Web of Science ®Google Scholar
• Abubaker J, Bavi PP, Al-Harbi S, et al. PIK3CA mutations are mutually exclusive with PTEN loss in diffuse large B-cell lymphoma. Leukemia. 2007;21(11):2368–2370. doi:10.1038/sj.leu.2404873.
   PubMed Web of Science ®Google Scholar
• Psyrri A, Papageorgiou S, Liakata E, et al. Phosphatidylinositol 3’-kinase catalytic subunit alpha gene amplification contributes to the pathogenesis of mantle cell lymphoma. Clin Cancer Res. 2009;15(18):5724–5732. doi:10.1158/1078-0432.CCR-08-3215.
   PubMed Web of Science ®Google Scholar
• Westin JR. Status of PI3K/Akt/mTOR pathway inhibitors in lymphoma. Clin Lymphoma Myeloma Leuk. 2014;14(5):335–342. doi:10.1016/j.clml.2014.01.007.
   PubMed Web of Science ®Google Scholar
• Liang J, Zubovitz J, Petrocelli T, et al. PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Nat Med. 2002;8(10):1153–1160. doi:10.1038/nm761.
   PubMed Web of Science ®Google Scholar
• Héron-Milhavet L, Franckhauser C, Rana V, et al. Only Akt1 is required for proliferation, while Akt2 promotes cell cycle exit through p21 binding. Mol Cell Biol. 2006;26(22):8267–8280. doi:10.1128/MCB.00201-06.
   PubMed Web of Science ®Google Scholar
• Georgakis GV, Li Y, Rassidakis GZ, et al. Inhibition of the phosphatidylinositol-3 kinase/Akt promotes G1 cell cycle arrest and apoptosis in Hodgkin lymphoma. Br J Haematol. 2006;132(4):503–511. doi:10.1111/j.1365-2141.2005.05881.x.
   PubMed Web of Science ®Google Scholar
• Uddin S, Hussain AR, Siraj AK, et al. Role of phosphatidylinositol 3’-kinase/AKT pathway in diffuse large B-cell lymphoma survival. Blood. 2006;108(13):4178–4186. doi:10.1182/blood-2006-04-016907.
   PubMed Web of Science ®Google Scholar
• Zhang X, Wu Y, Sun X, et al. The PI3K/AKT/mTOR signaling pathway is aberrantly activated in primary Central nervous system lymphoma and correlated with a poor prognosis. BMC Cancer. 2022;22(1):190. doi:10.1186/s12885-022-09275-z.
   PubMed Web of Science ®Google Scholar
• Rassidakis GZ, Feretzaki M, Atwell C, et al. Inhibition of Akt increases p27Kip1 levels and induces cell cycle arrest in anaplastic large cell lymphoma. Blood. 2005;105(2):827–829. doi:10.1182/blood-2004-06-2125.
   PubMed Web of Science ®Google Scholar
• Cai Q, Deng H, Xie D, et al. Phosphorylated AKT protein is overexpressed in human peripheral T-cell lymphomas and predicts decreased patient survival. Clin Lymphoma Myeloma Leuk. 2012;12(2):106–112. doi:10.1016/j.clml.2011.12.002.
   PubMed Web of Science ®Google Scholar
• Woyach JA, Bojnik E, Ruppert AS, et al. Bruton’s tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL). Blood. 2014;123(8):1207–1213. doi:10.1182/blood-2013-07-515361.
   PubMed Web of Science ®Google Scholar
• Wang H, Zhang W, Yang J, et al. The resistance mechanisms and treatment strategies of BTK inhibitors in B-cell lymphoma. Hematol Oncol. 2021;39(5):605–615. doi:10.1002/hon.2933.
   PubMed Web of Science ®Google Scholar
• Kapoor I, Li Y, Sharma A, et al. Resistance to BTK inhibition by ibrutinib can be overcome by preventing FOXO3a nuclear export and PI3K/AKT activation in B-cell lymphoid malignancies. Cell Death Dis. 2019;10(12):924. doi:10.1038/s41419-019-2158-0.
   PubMedGoogle Scholar
• Obrador-Hevia A, Serra-Sitjar M, Rodríguez J, et al. The tumour suppressor FOXO3 is a key regulator of mantle cell lymphoma proliferation and survival. Br J Haematol. 2012;156(3):334–345. doi:10.1111/j.1365-2141.2011.08951.x.
   PubMed Web of Science ®Google Scholar
• Bu L, Wang H, Pan JA, et al. PTEN suppresses tumorigenesis by directly dephosphorylating Akt. Signal Transduct Target Ther. 2021;6(1):262.
   PubMed Web of Science ®Google Scholar
• Vallois D, Dobay MP, Morin RD, et al. Activating mutations in genes related to TCR signaling in angioimmunoblastic and other follicular helper T-cell-derived lymphomas. Blood. 2016;128(11):1490–1502. doi:10.1182/blood-2016-02-698977.
   PubMed Web of Science ®Google Scholar
• Pfeifer M, Grau M, Lenze D, et al. PTEN loss defines a PI3K/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma. Proc Natl Acad Sci U S A. 2013;110(30):12420–12425. doi:10.1073/pnas.1305656110.
   PubMed Web of Science ®Google Scholar
• Xia Z, Zhang X, Liu P, et al. GNA13 regulates BCL2 expression and the sensitivity of GCB-DLBCL cells to BCL2 inhibitors in a palmitoylation-dependent manner. Cell Death Dis. 2021;12(1):54. doi:10.1038/s41419-020-03311-1.
   PubMed Web of Science ®Google Scholar
• Desch AK, Hartung K, Botzen A, et al. Genotyping circulating tumor DNA of pediatric hodgkin lymphoma. Leukemia. 2020;34(1):151–166. doi:10.1038/s41375-019-0541-6.
   PubMed Web of Science ®Google Scholar
• Li Y, Tian Z, Tan Y, et al. Bmi-1-induced miR-27a and miR-155 promote tumor metastasis and chemoresistance by targeting RKIP in gastric cancer. Mol Cancer. 2020;19(1):109. doi:10.1186/s12943-020-01229-y.
   PubMed Web of Science ®Google Scholar
• Zaczek A, Jóźwiak P, Ciesielski P, et al. Relationship between polycomb-group protein BMI-1 and phosphatases regulating AKT phosphorylation level in endometrial cancer. J Cell Mol Med. 2020;24(2):1300–1310. doi:10.1111/jcmm.14782.
   PubMed Web of Science ®Google Scholar
• Yang XX, Ma M, Sang MX, et al. BMI-1 suppression increases the radiosensitivity of oesophageal carcinoma via the PI3K/Akt signaling pathway. Oncol Rep. 2018;39(2):667–678.
   PubMed Web of Science ®Google Scholar
• Song Y, Yang Z, Li W, et al. The study of the mechanism of BMI-1 promoting the lymphoma growth in nude mice via activating PI3K/AKT signaling pathway. Modern Oncol. 2023;31(06):985–991.
   Google Scholar
• Wang C, Zhang J, Yin J, et al. Alternative approaches to target myc for cancer treatment. Signal Transduct Target Ther. 2021;6(1):117.
   PubMed Web of Science ®Google Scholar
• López C, Burkhardt B, Chan JKC, et al. Burkitt lymphoma. Nat Rev Dis Primers. 2022;8(1):78. doi:10.1038/s41572-022-00404-3.
   PubMedGoogle Scholar
• Sander S, Calado DP, Srinivasan L, et al. Synergy between PI3K signaling and MYC in burkitt lymphomagenesis. Cancer Cell. 2012;22(2):167–179. doi:10.1016/j.ccr.2012.06.012.
   PubMed Web of Science ®Google Scholar
• Dal Col J, Zancai P, Terrin L, et al. Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma. Blood. 2008;111(10):5142–5151. doi:10.1182/blood-2007-07-103481.
   PubMed Web of Science ®Google Scholar
• Wlodarski P, Kasprzycka M, Liu X, et al. Activation of mammalian target of rapamycin in transformed B lymphocytes is nutrient dependent but independent of Akt, mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, insulin growth factor-I, and serum. Cancer Res. 2005;65(17):7800–7808. doi:10.1158/0008-5472.CAN-04-4180.
   PubMed Web of Science ®Google Scholar
• Yap TA, Garrett MD, Walton MI, et al. Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. Curr Opin Pharmacol. 2008;8(4):393–412. doi:10.1016/j.coph.2008.08.004.
   PubMed Web of Science ®Google Scholar
• Mahadevan D, Chiorean EG, Harris WB, et al. Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies. Eur J Cancer. 2012;48(18):3319–3327. doi:10.1016/j.ejca.2012.06.027.
   PubMed Web of Science ®Google Scholar
• Kondapaka SB, Singh SS, Dasmahapatra GP, et al. A novel alkylphospholipid, inhibits protein kinase B activation. Mol Cancer Ther. 2003;2(11):1093–1103.
   PubMed Web of Science ®Google Scholar
• Guidetti A, Viviani S, Marchiano A, et al. Dual targeted therapy with the AKT inhibitor perifosine and the multikinase inhibitor sorafenib in patients with relapsed/refractory lymphomas: final results of a phase II trial. ASH Annual Meeting Abstracts. 2012;1203679.
   Google Scholar
• Witzig TE, Geyer SM, Ghobrial I, et al. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol. 2005;23(23):5347–5356. doi:10.1200/JCO.2005.13.466.
   PubMed Web of Science ®Google Scholar
• Kumar S, Mikhael JR, LaPlant BR, et al. Phase I trial of a novel combination of an HDAC inhibitor (LBH589) and an mTOR inhibitor (RAD001) in lymphoid and plasma cell malignancies. ASH Annual Meeting Abstracts. 2011;118:2682.
   Google Scholar
• Smith SM, van Besien K, Karrison T, et al. Temsirolimus has activity in non-mantle cell non-Hodgkin’s lymphoma subtypes: the university of Chicago phase II consortium. J Clin Oncol. 2010;28(31):4740–4746. doi:10.1200/JCO.2010.29.2813.
   PubMed Web of Science ®Google Scholar
• Giridharan S, Srinivasan M. Mechanisms of NF-κB p65 and strategies for therapeutic manipulation. J Inflamm Res. 2018;11:407–419. doi:10.2147/JIR.S140188.
   PubMed Web of Science ®Google Scholar
• Grondona P, Bucher P, Schulze-Osthoff K, et al. NF-κB activation in lymphoid malignancies: genetics, signaling, and targeted therapy. Biomedicines. 2018;6(2):38. doi:10.3390/biomedicines6020038.
   PubMed Web of Science ®Google Scholar
• Mitchell JP, Carmody RJ. NF-κB and the transcriptional control of inflammation. Int Rev Cell Mol Biol. 2018;335:41–84.
   PubMed Web of Science ®Google Scholar
• Staudt LM. Oncogenic activation of NF-kappaB. Cold Spring Harb Perspect Biol. 2010;2(6):a000109–a000109. doi:10.1101/cshperspect.a000109.
   PubMed Web of Science ®Google Scholar
• Lim KH, Yang Y, Staudt LM. Pathogenetic importance and therapeutic implications of NF-κB in lymphoid malignancies. Immunol Rev. 2012;246(1):359–378. doi:10.1111/j.1600-065X.2012.01105.x.
   PubMedGoogle Scholar
• Bargou RC, Leng C, Krappmann D, et al. High-level nuclear NF-kappa B and oct-2 is a common feature of cultured hodgkin/Reed-Sternberg cells. Blood. 1996;87(10):4340–4347. doi:10.1182/blood.V87.10.4340.bloodjournal87104340.
   PubMed Web of Science ®Google Scholar
• Davis RE, Brown KD, Siebenlist U, et al. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med. 2001;194(12):1861–1874. doi:10.1084/jem.194.12.1861.
   PubMed Web of Science ®Google Scholar
• Herishanu Y, Pérez-Galán P, Liu D, et al. The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood. 2011;117(2):563–574. doi:10.1182/blood-2010-05-284984.
   PubMed Web of Science ®Google Scholar
• Rahal R, Frick M, Romero R, et al. Pharmacological and genomic profiling identifies NF-κB-targeted treatment strategies for mantle cell lymphoma. Nat Med. 2014;20(1):87–92. doi:10.1038/nm.3435.
   PubMed Web of Science ®Google Scholar
• Lenz G, Davis RE, Ngo VN, et al. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science. 2008;319(5870):1676–1679. doi:10.1126/science.1153629.
   PubMed Web of Science ®Google Scholar
• Compagno M, Lim WK, Grunn A, et al. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature. 2009;459(7247):717–721. doi:10.1038/nature07968.
   PubMed Web of Science ®Google Scholar
• Ngo VN, Young RM, Schmitz R, et al. Oncogenically active MYD88 mutations in human lymphoma. Nature. 2011;470(7332):115–119. doi:10.1038/nature09671.
   PubMed Web of Science ®Google Scholar
• Lu D, Thompson JD, Gorski GK, et al. Alterations at the rel locus in human lymphoma. Oncogene. 1991;6(7):1235–1241.
   PubMed Web of Science ®Google Scholar
• Bertin J, Wang L, Guo Y, et al. CARD11 and CARD14 are novel caspase recruitment domain (CARD)/membrane-associated guanylate kinase (MAGUK) family members that interact with BCL10 and activate NF-kappa B. J Biol Chem. 2001;276(15):11877–11882. doi:10.1074/jbc.M010512200.
   PubMed Web of Science ®Google Scholar
• Gaide O, Favier B, Legler DF, et al. CARMA1 is a critical lipid raft-associated regulator of TCR-induced NF-kappa B activation. Nat Immunol. 2002;3(9):836–843. doi:10.1038/ni830.
   PubMed Web of Science ®Google Scholar
• Vilimas T, Mascarenhas J, Palomero T, et al. Targeting the NF-kappaB signaling pathway in Notch1-induced T-cell leukemia. Nat Med. 2007;13(1):70–77. doi:10.1038/nm1524.
   PubMed Web of Science ®Google Scholar
• Davis RE, Ngo VN, Lenz G, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature. 2010;463(7277):88–92.doi:10.1038/nature08638.
   PubMed Web of Science ®Google Scholar
• Wilson WH, Young RM, Schmitz R, et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med. 2015;21(8):922–926. doi:10.1038/nm.3884.
   PubMed Web of Science ®Google Scholar
• Dai B, Grau M, Juilland M, et al. B-cell receptor-driven MALT1 activity regulates MYC signaling in mantle cell lymphoma. Blood. 2017;129(3):333–346. doi:10.1182/blood-2016-05-718775.
   PubMed Web of Science ®Google Scholar
• Hailfinger S, Lenz G, Ngo V, et al. Essential role of MALT1 protease activity in activated B cell-like diffuse large B-cell lymphoma. Proc Natl Acad Sci U S A. 2009;106(47):19946–19951. doi:10.1073/pnas.0907511106.
   PubMed Web of Science ®Google Scholar
• Kelly PN, Romero DL, Yang Y, et al. Selective interleukin-1 receptor-associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy. J Exp Med. 2015;212(13):2189–2201. doi:10.1084/jem.20151074.
   PubMed Web of Science ®Google Scholar